Objective To investigate the differences in biological features between male and female patients with obstructive sleep apnea-hypopnea syndrome( OSAHS) . Methods 192 cases of patients with snoring were analyzed in the Sleep Medicine Center of West ChinaHospital fromSeptember 2004 to February 2005. The standard sleep disorder questionnaires, neck circumference, hight, weight, and all night polysomnography ( PSG) were evaluated. The clinical features of the male and female patients with OSAHS were compared. Results 170 cases of patients met the criteria of OSAHS for the apnea-hypopnea index ( AHI) more than 5 times per hour. Male gender accounted for 90% of the total patients ( male vs. female 153 vs. 17, 9∶1) . The age of male patients with OSAHS was younger than that of female ( 45. 7 ±11. 4 yearsvs. 58. 0 ±6. 1 years, P = 0. 000) . Parameters including neck circumference ( 37. 6 ±3. 2 cm vs. 35. 6 ±3. 2 cm, P =0. 000) , waist/hip rate ( 0. 94 ±0. 04 vs. 0. 9 ±0. 06, P = 0. 000) , AHI ( 36. 4 ±25. 7 vs.21. 4 ±17. 4, P =0. 004) , oxygen desaturation index ( 34. 5 ±27. 4 vs. 22. 2 ±20. 8, P =0. 035) , the number of smoking ( 52. 9% vs. 5. 9% , P = 0. 000) and drinking ( 46. 4% vs. 5. 9% , P = 0. 001) were different among the male and female patients with OSAHS. On the other hand, the morning headache ( 70. 6% vs.26. 1%, P = 0. 005) , mouth dry( 76. 5% vs. 47. 7% , P = 0. 025) , bad temper ( 52. 9% vs. 19. 0% , P =0. 004) , and hypertension ( 52. 9% vs. 20. 9% , P =0. 007) were more common in the female patients with OSAHS. Conclusion There are significant differences between male and female patients with OSAHS in prevalence, age, symptoms, and severity of the disease.
ObjectiveTo analyze the trends and major risk factors of ICH disease burden by gender in China and globally from 1990 to 2021, and to predict ICH incidence and mortality in China and globally by gender from 2022 to 2046. MethodsBased on the Global Burden of Disease Study 2021 (GBD 2021), data on ICH in China and globally from 1990 to 2021 were collected. Age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), and age-standardized disability-adjusted life years (ASDR) were used to assess ICH disease burden and risk factors by gender. Joinpoint regression models were employed to calculate annual percentage change (APC) and average annual percentage change (AAPC) for trend analysis. The Bayesian age-period-cohort (BAPC) model was applied to predict ICH incidence and mortality from 2022 to 2046. ResultsFrom 1990 to 2021, ASIR, ASMR, and ASDR for ICH in China and globally showed declining trends across genders (P<0.05). For males in China and globally, the AAPC for ASIR was −1.63% (95%CI −1.69% to −1.57%) and −1.14% (95%CI −1.20% to −1.07%), respectively. For females in China and globally, the AAPC for ASIR was −2.27% (95%CI −2.35% to −2.18%) and −1.40% (95%CI −1.40% to −1.33%), respectively. The AAPC for ASMR in Chinese and global males was −1.81% (95%CI −2.07% to −1.55%) and −1.29% (95%CI −1.43% to −1.15%), respectively, while for females in China and globally, it was −2.74% (95%CI −2.94% to −2.54%) and −1.69% (95%CI −1.82% to −1.55%), respectively. The AAPC for ASDR in Chinese and global males was −1.91% (95%CI −2.11% to −1.72%) and −1.39% (95%CI −1.52% to −1.26%), respectively, and for females in China and globally, it was −2.93% (95%CI −3.07% to −2.79%) and −1.85% (95%CI −1.96% to −1.74%), respectively. By 2046, the predicted ASIR for ICH in Chinese and global males is projected to be 38.08/100 000 and 44.23/100 000, respectively, and 28.27/100 000 and 29.15/100 000 for Chinese and global females. The ASMR is predicted to reach 37.01/100 000 and 68.57/100 000 for Chinese and global males, and 22.39/100 000 and 29.45/100 000 for Chinese and global females, respectively. ConclusionThe disease burden of intracerebral hemorrhage (ICH) in China has demonstrated a declining trend, yet it persistently exceeds global averages and exhibits pronounced gender disparities. There is an urgent need to enhance focus on these gender−specific variations and implement precisely targeted interventions tailored to the distinct risk factor profiles of each gender, in order to achieve further reductions in ICH−related disease burden.